Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Highlights: Navigating Revenue ...

GuruFocus.com11-07

Revenue: $134 million for Q3 2024, a 7% decrease compared to the same period last year; $479 million for the nine months ended September 30, 2024, a 3% increase year-over-year. SPINRAZA Royalties: $57...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481409219?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Yxj07fHE617Wok8y.DIVuQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/524e87b43d1b4c6f2d8b0ed1802ba6fa","is_english":true,"pubTime":"2024-11-07 15:18","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481409219","market":"us","top_or_hot":-1,"title":"Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Highlights: Navigating Revenue ...","media":"GuruFocus.com","content":"<div>\n<p>Revenue: $134 million for Q3 2024, a 7% decrease compared to the same period last year; $479 million for the nine months ended September 30, 2024, a 3% increase year-over-year.\nSPINRAZA Royalties: $57...</p>\n\n<a href=\"https://finance.yahoo.com/news/ionis-pharmaceuticals-inc-ions-q3-071830013.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ionis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Highlights: Navigating Revenue ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIonis Pharmaceuticals Inc (IONS) Q3 2024 Earnings Call Highlights: Navigating Revenue ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-07 15:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/ionis-pharmaceuticals-inc-ions-q3-071830013.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Revenue: $134 million for Q3 2024, a 7% decrease compared to the same period last year; $479 million for the nine months ended September 30, 2024, a 3% increase year-over-year.\nSPINRAZA Royalties: $57...</p>\n\n<a href=\"https://finance.yahoo.com/news/ionis-pharmaceuticals-inc-ions-q3-071830013.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IONS","symbol_name":"Ionis Pharmaceuticals, Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/ionis-pharmaceuticals-inc-ions-q3-071830013.html","article_id":"2481409219","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Yxj07fHE617Wok8y.DIVuQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/524e87b43d1b4c6f2d8b0ed1802ba6fa"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481409219","pubTimestamp":1730963910,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Revenue: $134 million for Q3 2024, a 7% decrease compared to the same period last year; $479 million for the nine months ended September 30, 2024, a 3% increase year-over-year.SPINRAZA Royalties: $57 million for Q3 2024; $152 million year-to-date.WAINUA Product Sales: $23 million for Q3 2024; $44 million year-to-date, with a 44% increase in Q3 compared to Q2.Operating Expenses: SG&A expenses increased 13% for Q3 2024 and 26% year-to-date, driven by higher sales and marketing expenses.Cash Position: Projected to end 2024 with $2.2 billion in cash following a recent equity offering.Recent Milestone Payment: $30 million from AstraZeneca for UK approval of WAINUA.GuruFocus has detected 3 Warning Signs with IONS.Ionis Pharmaceuticals Inc  is on the verge of its first independent launch with olezarsen, targeting familial chylomicronemia syndrome , a rare disease with no approved treatments in the U.S.Ionis Pharmaceuticals Inc  has shown significant progress in its wholly owned neurology fran","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"IONS":"Ionis Pharmaceuticals, Inc"},"translate_title":"Ionis Pharmaceuticals Inc(IONS)2024年第三季度收益看涨期权亮点：收入导航...","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IONS":1},"content_text":"Revenue: $134 million for Q3 2024, a 7% decrease compared to the same period last year; $479 million for the nine months ended September 30, 2024, a 3% increase year-over-year.\nSPINRAZA Royalties: $57 million for Q3 2024; $152 million year-to-date.\nWAINUA Product Sales: $23 million for Q3 2024; $44 million year-to-date, with a 44% increase in Q3 compared to Q2.\nOperating Expenses: SG&A expenses increased 13% for Q3 2024 and 26% year-to-date, driven by higher sales and marketing expenses.\nCash Position: Projected to end 2024 with $2.2 billion in cash following a recent equity offering.\nEmployee Base: Over 1,000 employees as of the report.\n2024 Revenue Guidance: Expected to exceed $575 million.\nRecent Milestone Payment: $30 million from AstraZeneca for UK approval of WAINUA.\n\n\nWarning! GuruFocus has detected 3 Warning Signs with IONS.\n\nRelease Date: November 06, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nIonis Pharmaceuticals Inc (NASDAQ:IONS) is on the verge of its first independent launch with olezarsen, targeting familial chylomicronemia syndrome (FCS), a rare disease with no approved treatments in the U.S.\nThe company anticipates three additional independent launches over the next three years, indicating a strong pipeline and growth potential.\nIonis Pharmaceuticals Inc (NASDAQ:IONS) has shown significant progress in its wholly owned neurology franchise, including the advancement of ION582 for Angelman syndrome into Phase III development.\nThe company has generated positive data from its donidalorsen clinical program, which could become a preferred prophylactic treatment for hereditary angioedema (HAE).\nIonis Pharmaceuticals Inc (NASDAQ:IONS) has a robust financial position, with a recent equity offering extending its cash runway to support upcoming commercial launches and pipeline advancements.\n\n Negative Points \n\nIonis Pharmaceuticals Inc (NASDAQ:IONS) reported a 7% decrease in revenues for the third quarter compared to the same period last year, indicating potential financial challenges.\nThe company faces competition in the FCS market, with a competitor potentially entering the market a few quarters after Ionis Pharmaceuticals Inc (NASDAQ:IONS)'s launch.\nThere are concerns about the payer dynamics for olezarsen, given its likely high pricing as an ultra-rare disease treatment.\nThe Phase III cardio transform study for WAINUA has been extended to full completion, potentially delaying the data readout to the second half of 2026.\nIonis Pharmaceuticals Inc (NASDAQ:IONS) is still in discussions with the FDA regarding labeling for olezarsen, which could impact the timing and success of its launch.\n\n Q & A Highlights \nQ: How soon will Ionis Pharmaceuticals be able to launch olezarsen for FCS post-approval, and what are the expected pricing and labeling discussions? A: Brett Monia, CEO, stated that they are in labeling discussions with the FDA and are pleased with the progress. Kyle Jenne, EVP of Commercial, mentioned that the team is ready to launch by December 19, with product expected in the channel before year-end. Pricing will be in the ultra-rare category, expected to be communicated upon approval.\nQ: Will there be any interim looks during the Phase III Angelman study, and how was the primary endpoint determined? A: Brett Monia, CEO, confirmed there are no plans for interim data looks. The study design was robust, and the FDA was supportive of their proposal after minor discussions, indicating strong alignment on the primary endpoint.\nQ: What is the rationale for the timing of the cardio transform study readout, and has there been any change in the approach? A: Brett Monia, CEO, explained that the decision was made to run the study to full completion with all patients completing 140 weeks of treatment. This approach ensures the most comprehensive data set, with the readout expected in the second half of 2026.\nQ: How many FCS patients have been identified, and what is the strategy to saturate the market before competitors? A: Brett Monia, CEO, emphasized the importance of their medical affairs team in educating physicians and identifying patients. The nine-month lead over competitors is seen as significant, allowing for a strong initial launch and continued patient identification.\nQ: How does Ionis plan to handle payer dynamics for FCS, given the high pricing, and is there any plan to extend the ATTR cardiomyopathy study? A: Kyle Jenne, EVP of Commercial, noted that payers have been receptive to the pricing due to the ultra-rare nature of FCS. Brett Monia, CEO, mentioned that while the current plan is to complete the study at 140 weeks, they will consider extending it if beneficial for the drug.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481409219"}